Registration Dossier
Registration Dossier
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 200-293-7 | CAS number: 56-86-0
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data

Exposure related observations in humans: other data
Administrative data
- Endpoint:
- exposure-related observations in humans: other data
- Type of information:
- other: SIDS
- Adequacy of study:
- other information
- Reliability:
- 2 (reliable with restrictions)
- Rationale for reliability incl. deficiencies:
- data from handbook or collection of data
Data source
Referenceopen allclose all
- Reference Type:
- publication
- Title:
- SIDS for L-Glutamic acid
- Author:
- OECD
- Year:
- 2 013
- Report date:
- 2013
- Reference Type:
- publication
- Title:
- Serum glutamic acid levels and the occurrence of nausea and vomiting after the intravenous administration of amino acid mixtures
- Author:
- Levey S, Harroun JE, Smyth CJ, and Mich D
- Year:
- 1 949
- Bibliographic source:
- Journal of Laboratory and Clinical Medicine, 34, p.1238-1248
Materials and methods
Test guideline
- Qualifier:
- no guideline followed
Test material
- Specific details on test material used for the study:
- Test material equivalent to submission substance identity:
yes
Method
- Ethical approval:
- not specified
- Details on study design:
- The first eight subjects received infusions of solutions containing 5.05 gm. of partially neutralized glutamic acid per 400 mL of solution; the next nine subjects received infusions of a solution containing 10.1 gm. of glutamic acid for 400 mL.
Results and discussion
- Results:
- Only two of these subjects had serum free glutamic acid levels exceeding 12 mg per 100 mL. Nine subjects received the stronger solution, five of whom became nauseated or vomited. Forty-five percent of the subjects who had levels of glutamic acid above 12 mg per 100 mL became nauseated or vomited (Table 1, upper half) .Since many of the commercial protein digests are sterilized by filtration rather than autoclaving and since heat promotes the conversion of glutamic acid to pyrrolidone carboxylic acid, it was decided to repeat these studies using only glutamic acid solutions which had been sterilized by filtration, employing both the lower and higher doses (Table 1, lower half). When the lower dose was administered, two of the six subjects tested became nauseated or vomited; with the higher doses all of the eight subjects tested became ill. One subject vomited but had a blood glutamic acid level of only 7.5 mg per 100 mL.
Applicant's summary and conclusion
- Conclusions:
- There was a direct relationship between free serum glutamic acid and the occurrence of toxic effects following intravenous administration. When the serum free glutamic acid level reached 12-15 mg/100 mL, nausea and vomiting occurred in more than half of the subjects.
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.
